Recent 8-K filings for USAQ

• May 26, 2026, 8:30 AM ET other material materiality 0.60 positive item 7.01item 9.01

  QHSLab reports April 2026 unaudited revenue of $325,889, up 57% YoY; launches QHS Practice Access Network

  Unaudited April 2026 revenue $325,889, up 57% from $207,538 in April 2025.

• April 21, 2026, 7:59 PM ET earnings materiality 0.65 positive item 7.01item 9.01

  QHSLab reports 127% YoY ISP revenue growth to $370K in Q1 2026; launches GLP-1 support program

  Unaudited Q1 2026 ISP revenue of $370,000, up 127% from $163,000 in Q1 2025.

• March 31, 2026, 7:59 PM ET earnings materiality 0.70 positive item 7.01item 9.01

  QHSLab reports fiscal 2025 net income of $457K, revenue up 26% to $2.69M

  Revenue $2.69M (+26% YoY); net income $457,417 vs net loss $259,239 in 2024.

• January 26, 2026, 6:59 PM ET earnings materiality 0.75 positive item 7.01item 9.01

  QHSLab reports preliminary 2025 revenue up 25% to $2.68M, debt cut to $20k

  Revenue $2,676,074, up 25% YoY; gross profit $1,795,182, up 32% YoY.

• January 23, 2026, 6:59 PM ET debt materiality 0.55 neutral item 1.01item 3.02item 8.01item 9.01 ◈ Material Agreements

  QHSLab repurchases $470K promissory note with 1.57M shares, extinguishing related-party debt

  Repurchased and cancelled promissory note held by MedScience; outstanding principal and interest $470,529 as of Dec 31, 2025.

• January 16, 2026, 6:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  QHSLab initiates board expansion to add independent directors; convertible debt eliminated

  Process to add independent board members commenced; interviews and meetings with candidates underway.

• January 6, 2026, 6:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  QHSLab reports 32% revenue growth to $1.99M, eliminates most convertible debt, cash ~$630k

  Revenue $1.99M for nine months ended Sep 30, 2025 (+32% YoY); gross margin 66%.

• January 2, 2026, 6:59 PM ET other material materiality 0.45 neutral item 1.01item 3.02item 9.01 ◈ Material Agreements

  QHSLab converts $126,548 of note into 421,827 shares; extends remaining $20k to Dec 2026

  Converted $126,548 of principal and accrued interest into 421,827 common shares at $0.30/share.

• December 29, 2025, 6:59 PM ET other material materiality 0.70 positive item 1.01item 3.02item 7.01item 9.01 ◈ Material Agreements

  QHSLab raises $500K in equity, retires $1.4M convertible debt; clean balance sheet entering 2026

  Private placement of 1,666,663 shares at $0.30/share plus 416,666 warrants exercisable at $0.60 through Dec 2030.

• December 3, 2025, 6:59 PM ET other material materiality 0.55 neutral item 7.01item 9.01

  QHSLab launches Q-Cog cognitive assessment; pilot finds 54% high-risk in 168 patients

  Launched Q-Cog, a cloud-based digital tool for primary care screening of Mild Cognitive Impairment and dementia.

• December 1, 2025, 6:59 PM ET other material materiality 0.10 neutral item 7.01item 9.01

  QHSLab furnishes December 2025 corporate presentation on Form 8-K

  QHSLab, Inc. (USAQ) filed a Form 8-K on December 1, 2025, to furnish its December 2025 Corporate Presentation.

• November 24, 2025, 6:59 PM ET other material materiality 0.75 positive item 7.01item 9.01

  QHSLab nine-month revenue $1.99M; retires convertible notes, eliminates dilution overhang

  Nine-month 2025 revenue $1.99M, up 32% YoY from $1.51M; gross profit $1.32M.

• November 18, 2025, 6:59 PM ET earnings materiality 0.75 positive item 1.01item 2.04item 7.01item 9.01 ◈ Debt Financings

  QHSLab retires $1.4M in convertible notes for $300K; Q3 revenue up 35% to $737K

  Repurchased and cancelled $1.4M+ in defaulted convertible notes for $300K cash; conversion rights at $0.20/share eliminated.

• September 2, 2025, 7:59 PM ET other material materiality 0.50 neutral item 7.01item 9.01

  QHSLab launches Pediatric Health Assessment with multi-location Texas pediatric group

  Tool integrates behavioral screeners (PSC-17, SDQ) with allergy/asthma metrics (CARAT) and OTC medication use.

• July 8, 2025, 7:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  QHSLab (USAQ) opens first co-branded behavioral health center in Miami with QHS Healthcare

  First QHS Behavioral Healthcare Center (QBHC) opened in Miami on July 8, 2025, in partnership with Global Behavioral Healthcare Group Corp.

• June 3, 2025, 7:59 PM ET other material materiality 0.50 positive item 7.01item 9.01

  QHSLab publishes two peer-reviewed studies validating digital assessment tools in primary care

  Study in Journal of Psychosomatic Research: help-seeking behavior in allergic rhinitis reduces negative impact on anxiety and depression.

• May 21, 2025, 7:59 PM ET other material materiality 0.20 neutral item 7.01item 9.01

  QHSLab issues May 2025 corporate presentation without specific financial updates

  Presentation covers business and operations; no financial results or guidance included.

• May 16, 2025, 7:59 PM ET other material materiality 0.55 positive item 7.01item 9.01

  QHSLab in advanced debt restructuring talks with Catheter Precision to improve balance sheet

  Discussions to restructure OID Notes (previously held by Mercer Street Global Opportunity Fund) held by Catheter Precision.

• May 15, 2025, 7:59 PM ET earnings materiality 0.65 positive item 7.01item 9.01

  QHSLab Q1 revenue up 32% to $645K; gross margin expands to 66.6%

  Total revenue $645,419 vs $488,587 in Q1 2024, a 32.1% increase.

• February 26, 2025, 6:59 PM ET other material materiality 0.30 neutral item 7.01item 9.01

  QHSLab (USAQ) hires Hayden IR to boost investor visibility

  QHSLab engaged Hayden IR, a national investor relations firm, to raise visibility and strengthen relationships.

• February 25, 2025, 6:59 PM ET other material materiality 0.85 negative item 2.04item 9.01

  QHSLab receives $1.4M default notice on two convertible notes; expects not to pay by Feb 27

  Received Notice of Default from Mercer Street Global Opportunity Fund for two secured promissory notes (August 2021 and July 2022).

• February 18, 2025, 6:59 PM ET earnings materiality 0.65 positive item 7.01item 9.01

  QHSLab reports 98% Q4 revenue surge, first profitable year with net income of $69,188

  Q4 revenue $625,981 (+98% YoY); net income $40,838 vs loss $86,627 Q4 2023.

• February 11, 2025, 6:59 PM ET other material materiality 0.55 positive item 7.01item 9.01

  QHSLab announces co-marketing partnership with Town Total Compounding covering 200+ practices

  Partnership will introduce QHSLab's Integrated Service Program to over 200 primary care practices in Town Total's network.

• January 21, 2025, 6:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  QHSLab furnishes January 2025 Corporate Presentation without specific content

  Corporate presentation filed as Exhibit 99.1, made available on January 21, 2025.

• January 16, 2025, 6:59 PM ET other material materiality 0.20 neutral item 7.01item 9.01

  QHSLab to exhibit at Pri-Med South conference Feb 2025, targeting 5,000 primary care professionals

  Company will exhibit at Pri-Med South in Fort Lauderdale, Feb 6-8, 2025.

• December 16, 2024, 6:59 PM ET other material materiality 0.55 neutral item 7.01item 9.01

  QHSLab projects $10M revenue with 250-300 physicians at >65% gross margins

  Single provider using full suite can generate $30-50k annual revenue for QHSLab.

• December 13, 2024, 6:59 PM ET other material materiality 0.35 positive item 7.01item 9.01

  QHSLab and SDSU receive NSF invitation to submit STTR application for AIR-GUIDDE technology

  NSF invites QHSLab and South Dakota State University to submit full Phase I STTR application for AIR-GUIDDE drug delivery platform.

• November 25, 2024, 6:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  QHSLab reports Oct sales up 110% to $225k; APA abstracts accepted for 2025

  October 2024 unaudited sales ~$225,000, a 110% increase YoY; annualized run rate $2.7M.

• November 14, 2024, 6:59 PM ET earnings materiality 0.65 positive item 7.01item 9.01

  QHSLab Q3 revenue up 62% to $544K, net income $49.8K, gross margin 67.1%

  Revenue $544,285 (+62% YoY); gross margin 67.1% (up from 56.3%). Net income $49,765 vs ($82,000) loss in Q3 2023.

• October 22, 2024, 7:59 PM ET other material materiality 0.40 positive item 1.01item 3.02item 7.01item 9.01

  QHSLab adds psychiatry advisor Dr. Juan Oms; grants 100k shares in compensation

  Dr. Oms will provide strategic advisory services in psychiatry and behavioral health under a 24-month consulting agreement.

• October 21, 2024, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  QHSLab reports 40% revenue growth, positive cash flow, and strategic review

  Revenue increased 40% year-over-year to over $1.5 million in the third quarter of 2024.

• September 25, 2024, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  QHSLab secures $297K grant from global consumer health firm for allergic rhinitis digital study

  QHSLab received $297,360 grant from a Global Leader in Consumer Health to advance digital medicine for allergic rhinitis.

• September 17, 2024, 7:59 PM ET other material materiality 0.50 positive item 7.01item 9.01

  QHSLab doubles assessment completions to ~50K year-to-date; two abstracts accepted at ACAAI

  Platform processed ~50,000 assessments in 2024 YTD, more than double the same period in 2023.

• August 14, 2024, 7:59 PM ET earnings materiality 0.75 positive item 7.01item 9.01

  QHSLab reports strong Q2 2024: revenue +17%, gross margin 62.2%, net loss down 97% to $2.9K

  Q2 revenue $473,073 (+17% YoY); six-month revenue $961,660 (+27%).

• June 7, 2024, 7:59 PM ET other material materiality 0.75 negative item 4.01item 9.01

  QHSLab dismisses auditor Accell, engages Astra; prior reports included going concern uncertainty

  Dismissed Accell Audit & Compliance as independent auditor effective June 4, 2024.

• May 13, 2024, 7:59 PM ET earnings materiality 0.65 positive item 7.01item 9.01

  QHSLab Q1 revenue up 39% to $488K; posts positive operating income of $13.6K vs loss of $120.8K year ago

  Q1 2024 revenue $488,587 (+38.6% YoY); Integrated Service Program revenue surged 268% to $127,004.

• May 2, 2024, 7:59 PM ET leadership materiality 0.30 neutral item 7.01item 9.01

  QHSLab appoints Dr. Marcos Sanchez-Gonzalez as VP of Medical and Scientific Affairs

  Dr. Marcos Sanchez-Gonzalez appointed VP of Medical and Scientific Affairs effective May 2, 2024.

• April 26, 2024, 7:59 PM ET earnings materiality 0.65 positive item 7.01item 9.01

  QHSLab reports preliminary Q1 revenue $488,587, up 38% YoY; gross profit $286,157, up 53%

  Revenue of $488,587, up 38% from $352,799 in Q1 2023.

• April 18, 2024, 7:59 PM ET other materiality 0.20 neutral item 7.01item 9.01

  QHSLab furnishes corporate presentation; no specific financial data in filing

  Company furnished a corporate presentation for meetings with broker-dealers and investors.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

25 positive 2 negative 12 neutral

source · USAQ on sec.gov